<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Care</journal-id><journal-id journal-id-type="hwp">diacare</journal-id><journal-id journal-id-type="pmc">dcare</journal-id><journal-id journal-id-type="publisher-id">Diabetes Care</journal-id><journal-title>Diabetes Care</journal-title><issn pub-type="ppub">0149-5992</issn><issn pub-type="epub">1935-5548</issn><publisher><publisher-name>American Diabetes Association</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19196886</article-id><article-id pub-id-type="pmc">2671107</article-id><article-id pub-id-type="publisher-id">1862</article-id><article-id pub-id-type="doi">10.2337/dc08-1862</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject><subj-group><subject>Emerging Treatments and Technologies</subject></subj-group></subj-group></article-categories><title-group><article-title>Phosphodiesterase 5 Inhibition Improves β-Cell Function in Metabolic Syndrome</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hill</surname><given-names>Kevin D.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Eckhauser</surname><given-names>Aaron W.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Marney</surname><given-names>Annis</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Brown</surname><given-names>Nancy J.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="corresp" rid="cor1"></xref></contrib><aff id="aff1"><sup>1</sup>Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee; </aff><aff id="aff2"><sup>2</sup>Department of Surgery, Vanderbilt University Medical Center, Nashville, Tennessee; </aff><aff id="aff3"><sup>3</sup>Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.</aff></contrib-group><author-notes><corresp id="cor1">Corresponding author: Nancy J. Brown, <email>nancy.j.brown@vanderbilt.edu</email></corresp></author-notes><pub-date pub-type="ppub"><month>5</month><year>2009</year></pub-date><pub-date pub-type="epub"><day>5</day><month>2</month><year>2009</year></pub-date><volume>32</volume><issue>5</issue><fpage>857</fpage><lpage>859</lpage><history><date date-type="received"><day>17</day><month>10</month><year>2008</year></date><date date-type="accepted"><day>26</day><month>1</month><year>2009</year></date></history><copyright-statement>© 2009 by the American Diabetes Association.</copyright-statement><copyright-year>2009</copyright-year><license license-type="creative-commons"><p>Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">http://creativecommons.org/licenses/by-nc-nd/3.0/</ext-link> for details.</p></license><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="zdc00509000857.pdf"></self-uri><abstract><sec><title><offsets xml_i="3512" xml_f="3521" txt_i="11" txt_f="20">OBJECTIVE</offsets></title><p><offsets xml_i="3532" xml_f="3730" txt_i="21" txt_f="219">This study tested the hypothesis that phosphodiesterase 5 inhibition alone or in combination with ACE inhibition improves glucose homeostasis and fibrinolysis in individuals with metabolic syndrome.</offsets></p></sec><sec><title><offsets xml_i="3752" xml_f="3779" txt_i="221" txt_f="248">RESEARCH DESIGN AND METHODS</offsets></title><p><offsets xml_i="3790" xml_f="4076" txt_i="249" txt_f="535">Insulin sensitivity, β-cell function, and fibrinolytic parameters were measured in 18 adults with metabolic syndrome on 4 separate days after a randomized, crossover, double-blind, 3-week treatment with placebo, ramipril (10 mg/day), tadalafil (10 mg o.d.), and ramipril plus tadalafil.</offsets></p></sec><sec><title><offsets xml_i="4098" xml_f="4105" txt_i="537" txt_f="544">RESULTS</offsets></title><p><offsets xml_i="4116" xml_f="4357" txt_i="545" txt_f="786">Ramipril decreased systolic and diastolic blood pressure, ACE activity, and angiotensin II and increased plasma renin activity. Ramipril did not affect insulin sensitivity or β-cell function. In contrast, tadalafil improved β-cell function (</offsets><italic><offsets xml_i="4365" xml_f="4366" txt_i="786" txt_f="787">P</offsets></italic><offsets xml_i="4375" xml_f="4462" txt_i="787" txt_f="874"> = 0.01). This effect was observed in women (331.9 ± 209.3 vs. 154.4 ± 48.0 32 μ · mmol</offsets><sup><offsets xml_i="4467" xml_f="4469" txt_i="874" txt_f="876">−1</offsets></sup><offsets xml_i="4475" xml_f="4479" txt_i="876" txt_f="880"> · l</offsets><sup><offsets xml_i="4484" xml_f="4486" txt_i="880" txt_f="882">−1</offsets></sup><offsets xml_i="4492" xml_f="4545" txt_i="882" txt_f="935">, respectively, for tadalafil treatment vs. placebo; </offsets><italic><offsets xml_i="4553" xml_f="4554" txt_i="935" txt_f="936">P</offsets></italic><offsets xml_i="4563" xml_f="4641" txt_i="936" txt_f="1014"> = 0.01) but not in men. There was no effect of any treatment on fibrinolysis.</offsets></p></sec><sec><title><offsets xml_i="4663" xml_f="4674" txt_i="1016" txt_f="1027">CONCLUSIONS</offsets></title><p><offsets xml_i="4685" xml_f="4799" txt_i="1028" txt_f="1142">Phosphodiesterase 5 inhibition may represent a novel strategy for improving β-cell function in metabolic syndrome.</offsets></p></sec></abstract></article-meta></front><body><p><offsets xml_i="4852" xml_f="4997" txt_i="1151" txt_f="1296">Metabolic syndrome affects over 20% of U.S. adults, predicts diabetes, and will soon overtake smoking as the premier cardiovascular risk factor (</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="5028" xml_f="5029" txt_i="1296" txt_f="1297">1</offsets></xref><offsets xml_i="5036" xml_f="5147" txt_i="1297" txt_f="1408">). Progression to type 2 diabetes results from impaired insulin sensitivity and pancreatic β-cell dysfunction (</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="5178" xml_f="5179" txt_i="1408" txt_f="1409">2</offsets></xref><offsets xml_i="5186" xml_f="5187" txt_i="1409" txt_f="1410">,</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="5218" xml_f="5219" txt_i="1410" txt_f="1411">3</offsets></xref><offsets xml_i="5226" xml_f="5341" txt_i="1411" txt_f="1526">). ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) may decrease diabetes in high-risk individuals (</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="5372" xml_f="5373" txt_i="1526" txt_f="1527">4</offsets></xref><offsets xml_i="5380" xml_f="5503" txt_i="1527" txt_f="1650">). These agents can improve insulin sensitivity by preventing inhibitory effects of angiotensin II on GLUT4 translocation (</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="5534" xml_f="5535" txt_i="1650" txt_f="1651">5</offsets></xref><offsets xml_i="5542" xml_f="5659" txt_i="1651" txt_f="1768">) or improve insulin secretion by preventing angiotensin II type 1 receptor–dependent inhibition of insulin release (</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="5690" xml_f="5691" txt_i="1768" txt_f="1769">6</offsets></xref><offsets xml_i="5698" xml_f="5700" txt_i="1769" txt_f="1771">).</offsets></p><p><offsets xml_i="5707" xml_f="5807" txt_i="1772" txt_f="1872">Nitric oxide (NO) may also contribute to salutary effects of ACEIs and ARBs on glucose homeostasis (</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="5838" xml_f="5839" txt_i="1872" txt_f="1873">7</offsets></xref><offsets xml_i="5846" xml_f="5932" txt_i="1873" txt_f="1959">). NO stimulates muscle glucose uptake through cyclic guanosine monophosphate (cGMP) (</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="5963" xml_f="5964" txt_i="1959" txt_f="1960">7</offsets></xref><offsets xml_i="5971" xml_f="6091" txt_i="1960" txt_f="2080">). In mice, inhibiting cGMP degradation by phosphodiesterase 5 increases insulin sensitivity and muscle glucose uptake (</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="6122" xml_f="6123" txt_i="2080" txt_f="2081">8</offsets></xref><offsets xml_i="6130" xml_f="6254" txt_i="2081" txt_f="2205">). cGMP decreases apoptosis and increases intracellular calcium in pancreatic β-cells, suggesting an insulinotropic effect (</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="6285" xml_f="6286" txt_i="2205" txt_f="2206">9</offsets></xref><offsets xml_i="6293" xml_f="6294" txt_i="2206" txt_f="2207">,</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="6326" xml_f="6328" txt_i="2207" txt_f="2209">10</offsets></xref><offsets xml_i="6335" xml_f="6494" txt_i="2209" txt_f="2368">). We tested the hypothesis that decreasing degradation of cGMP would enhance any effect of ACE inhibition on insulin sensitivity or β-cell function in humans.</offsets></p><sec><title><offsets xml_i="6510" xml_f="6537" txt_i="2369" txt_f="2396">RESEARCH DESIGN AND METHODS</offsets></title><p><offsets xml_i="6548" xml_f="6714" txt_i="2397" txt_f="2563">Subjects with metabolic syndrome (National Cholesterol Education Program criteria) participated in a double-blind, randomized, and placebo-controlled crossover study.</offsets></p><p><offsets xml_i="6721" xml_f="6820" txt_i="2564" txt_f="2663">Each subject was studied four times (see supplementary Fig. A1, available in an online appendix at </offsets><ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/cgi/content/full/dc08-1862/DC1"><offsets xml_i="6927" xml_f="6990" txt_i="2663" txt_f="2726">http://care.diabetesjournals.org/cgi/content/full/dc08-1862/DC1</offsets></ext-link><offsets xml_i="7001" xml_f="7302" txt_i="2726" txt_f="3027">). Antihypertensive medications were withdrawn 3 weeks before the study. Participants were then randomized to one of four 3-week treatments (placebo plus placebo, ramipril [10 mg/day] plus placebo, tadalafil [10 mg o.d.] plus placebo, and ramipril plus tadalafil) separated by a 1-week washout period.</offsets></p><p><offsets xml_i="7309" xml_f="7717" txt_i="3028" txt_f="3436">During the last week of treatment, subjects ate a nitrate-, sodium-, and calorie-controlled diet. On the last day, they collected a 24-h urine sample and fasted overnight. At 0730 h, supine blood pressure and heart rate were measured thrice, 2 min apart. Blood was drawn via venous catheter for plasma renin activity (PRA), ACE activity, angiotensin II, aldosterone, fibrinolytic parameters, NO metabolites, </offsets><sc><offsets xml_i="7721" xml_f="7722" txt_i="3436" txt_f="3437">l</offsets></sc><offsets xml_i="7727" xml_f="7740" txt_i="3437" txt_f="3450">-citrulline, </offsets><sc><offsets xml_i="7744" xml_f="7745" txt_i="3450" txt_f="3451">l</offsets></sc><offsets xml_i="7750" xml_f="7770" txt_i="3451" txt_f="3471">-arginine, and cGMP.</offsets></p><p><offsets xml_i="7777" xml_f="8165" txt_i="3472" txt_f="3860">At 0800 h, subjects underwent a frequently sampled intravenous glucose tolerance test (additional information available in the online appendix). Insulin sensitivity index, glucose effectiveness index, homeostasis model assessment of insulin resistance, and β-cell function were calculated using a modified version of minimal model (MINMOD) formulas. Acute insulin response to glucose (AIR</offsets><sub><offsets xml_i="8170" xml_f="8171" txt_i="3860" txt_f="3861">g</offsets></sub><offsets xml_i="8177" xml_f="8291" txt_i="3861" txt_f="3975">) was assessed from the area under the insulin curve for the first 10 min following dextrose infusion. Because AIR</offsets><sub><offsets xml_i="8296" xml_f="8297" txt_i="3975" txt_f="3976">g</offsets></sub><offsets xml_i="8303" xml_f="8417" txt_i="3976" txt_f="4090"> disregards changes in insulin sensitivity, we used disposition index, calculated from insulin sensitivity and AIR</offsets><sub><offsets xml_i="8422" xml_f="8423" txt_i="4090" txt_f="4091">g</offsets></sub><offsets xml_i="8429" xml_f="8480" txt_i="4091" txt_f="4142">, as a more reliable indicator of β-cell function (</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="8511" xml_f="8512" txt_i="4142" txt_f="4143">2</offsets></xref><offsets xml_i="8519" xml_f="8521" txt_i="4143" txt_f="4145">).</offsets></p></sec><sec sec-type="results"><title><offsets xml_i="8562" xml_f="8569" txt_i="4147" txt_f="4154">RESULTS</offsets></title><p><offsets xml_i="8580" xml_f="8682" txt_i="4155" txt_f="4257">Eighteen subjects completed the study. Characteristics can be found in supplementary Tables A1 and A2.</offsets></p><sec><title><offsets xml_i="8698" xml_f="8739" txt_i="4258" txt_f="4299">Hemodynamic and renin-angiotensin effects</offsets></title><p><offsets xml_i="8750" xml_f="9031" txt_i="4300" txt_f="4581">Sodium excretion was similar during all treatments (supplementary Table A3). Ramipril significantly increased PRA and decreased ACE activity and angiotensin II (supplementary Table A3). Tadalafil did not affect the renin-angiotensin-aldosterone system or alter effects of ramipril.</offsets></p><p><offsets xml_i="9038" xml_f="9065" txt_i="4582" txt_f="4609">Ramipril reduced systolic (</offsets><italic><offsets xml_i="9073" xml_f="9074" txt_i="4609" txt_f="4610">P</offsets></italic><offsets xml_i="9083" xml_f="9093" txt_i="4610" txt_f="4620"> = 0.01) (</offsets><xref ref-type="fig" rid="F1"><offsets xml_i="9123" xml_f="9129" txt_i="4620" txt_f="4626">Fig. 1</offsets></xref><offsets xml_i="9136" xml_f="9168" txt_i="4626" txt_f="4658">) and diastolic blood pressure (</offsets><italic><offsets xml_i="9176" xml_f="9177" txt_i="4658" txt_f="4659">P</offsets></italic><offsets xml_i="9186" xml_f="9311" txt_i="4659" txt_f="4781"> &lt; 0.001). Tadalafil did not affect blood pressure but tended to enhance the ramipril effect on diastolic blood pressure (</offsets><italic><offsets xml_i="9319" xml_f="9320" txt_i="4781" txt_f="4782">P</offsets></italic><offsets xml_i="9329" xml_f="9419" txt_i="4782" txt_f="4872"> = 0.06 for interaction, controlling for sex and race). No treatments impacted heart rate.</offsets></p><fig id="F1" position="float"><label><offsets xml_i="9460" xml_f="9468" txt_i="4873" txt_f="4881">Figure 1</offsets></label><caption><p><offsets xml_i="9488" xml_f="9758" txt_i="4881" txt_f="5151">Effect of treatment on systolic blood pressure (BP), diastolic blood pressure, insulin sensitivity, and β-cell function. Sex and race were included as covariates in the ANOVA. For β-cell function, data are presented as estimated marginal means after controlling for sex.</offsets></p></caption><graphic xlink:href="zdc0050974900001"></graphic></fig></sec><sec><title><offsets xml_i="9845" xml_f="9864" txt_i="5153" txt_f="5172">Glucose homeostasis</offsets></title><p><offsets xml_i="9875" xml_f="9936" txt_i="5173" txt_f="5234">Neither ramipril nor tadalafil affected insulin sensitivity (</offsets><xref ref-type="fig" rid="F1"><offsets xml_i="9966" xml_f="9972" txt_i="5234" txt_f="5240">Fig. 1</offsets></xref><offsets xml_i="9979" xml_f="10144" txt_i="5240" txt_f="5405">). No treatments altered glucose effectiveness, a measure of insulin-independent glucose disposal (0.017 ± 0.006, 0.017 ± 0.008, 0.017 ± 0.009, and 0.015 ± 0.007 min</offsets><sup><offsets xml_i="10149" xml_f="10151" txt_i="5405" txt_f="5407">−1</offsets></sup><offsets xml_i="10157" xml_f="10235" txt_i="5407" txt_f="5485"> for placebo, tadalafil, ramipril, and ramipril plus tadalafil, respectively).</offsets></p><p><offsets xml_i="10242" xml_f="10372" txt_i="5486" txt_f="5616">Ramipril did not affect β-cell function. In contrast, tadalafil significantly improved β-cell function after controlling for sex (</offsets><italic><offsets xml_i="10380" xml_f="10381" txt_i="5616" txt_f="5617">P</offsets></italic><offsets xml_i="10390" xml_f="10400" txt_i="5617" txt_f="5627"> = 0.01) (</offsets><xref ref-type="fig" rid="F1"><offsets xml_i="10430" xml_f="10436" txt_i="5627" txt_f="5633">Fig. 1</offsets></xref><offsets xml_i="10443" xml_f="10474" txt_i="5633" txt_f="5664">) or baseline fasting glucose (</offsets><italic><offsets xml_i="10482" xml_f="10483" txt_i="5664" txt_f="5665">P</offsets></italic><offsets xml_i="10492" xml_f="10640" txt_i="5665" txt_f="5813"> = 0.05). In a subgroup analysis, tadalafil improved β-cell function in women (154.4 ± 48.0, 331.9 ± 209.3, 229.1 ± 202.1, and 259.7 ± 95.8 μ · mmol</offsets><sup><offsets xml_i="10645" xml_f="10647" txt_i="5813" txt_f="5815">−1</offsets></sup><offsets xml_i="10653" xml_f="10657" txt_i="5815" txt_f="5819"> · l</offsets><sup><offsets xml_i="10662" xml_f="10664" txt_i="5819" txt_f="5821">−1</offsets></sup><offsets xml_i="10670" xml_f="10761" txt_i="5821" txt_f="5912"> during placebo, tadalafil, ramipril, and ramipril plus tadalafil treatment, respectively; </offsets><italic><offsets xml_i="10769" xml_f="10770" txt_i="5912" txt_f="5913">P</offsets></italic><offsets xml_i="10779" xml_f="11023" txt_i="5913" txt_f="6157"> = 0.01 for tadalafil effect) but not in men. There was a trend toward improved β-cell function during tadalafil treatment in individuals with baseline fasting hyperglycemia (195.3 ± 103.1, 278.7 ± 114.0, 157.2 ± 52.6, and 210.6 ± 72.3 μ · mmol</offsets><sup><offsets xml_i="11028" xml_f="11030" txt_i="6157" txt_f="6159">−1</offsets></sup><offsets xml_i="11036" xml_f="11040" txt_i="6159" txt_f="6163"> · l</offsets><sup><offsets xml_i="11045" xml_f="11047" txt_i="6163" txt_f="6165">−1</offsets></sup><offsets xml_i="11053" xml_f="11144" txt_i="6165" txt_f="6256"> during placebo, tadalafil, ramipril, and ramipril plus tadalafil treatment, respectively; </offsets><italic><offsets xml_i="11152" xml_f="11153" txt_i="6256" txt_f="6257">P</offsets></italic><offsets xml_i="11162" xml_f="11332" txt_i="6257" txt_f="6427"> = 0.06 for tadalafil) but not in subjects with normal fasting glucose. There was no effect of race and no interactive effect of ramipril or tadalafil on β-cell function.</offsets></p><p><offsets xml_i="11339" xml_f="11349" txt_i="6428" txt_f="6438">Ramipril (</offsets><italic><offsets xml_i="11357" xml_f="11358" txt_i="6438" txt_f="6439">P</offsets></italic><offsets xml_i="11367" xml_f="11391" txt_i="6439" txt_f="6463"> = 0.02) and tadalafil (</offsets><italic><offsets xml_i="11399" xml_f="11400" txt_i="6463" txt_f="6464">P</offsets></italic><offsets xml_i="11409" xml_f="11767" txt_i="6464" txt_f="6822"> = 0.02) improved the disposition index in women but not in men after controlling for fasting glucose. This was attributable to a synergistic effect of ramipril and tadalafil on the disposition index (1,001.8 ± 909.5, 977.8 ± 728.5, 1,308.8 ± 976.2, and 1,982.2 ± 1,982.2 units during placebo, tadalafil, ramipril, and ramipril plus tadalafil, respectively; </offsets><italic><offsets xml_i="11775" xml_f="11776" txt_i="6822" txt_f="6823">P</offsets></italic><offsets xml_i="11785" xml_f="11822" txt_i="6823" txt_f="6860"> = 0.05 for ramipril plus tadalafil).</offsets></p></sec></sec><sec sec-type="conclusions"><title><offsets xml_i="11873" xml_f="11884" txt_i="6863" txt_f="6874">CONCLUSIONS</offsets></title><p><offsets xml_i="11895" xml_f="12146" txt_i="6875" txt_f="7126">The phosphodiesterase 5 inhibitor tadalafil, alone or in combination with ramipril, improved basal and glucose-stimulated β-cell function. The latter effect was independent of insulin sensitivity, as indicated by improvement in the disposition index (</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="12177" xml_f="12178" txt_i="7126" txt_f="7127">2</offsets></xref><offsets xml_i="12185" xml_f="12187" txt_i="7127" txt_f="7129">).</offsets></p><p><offsets xml_i="12194" xml_f="12389" txt_i="7130" txt_f="7325">Metabolic syndrome, an insulin-resistant state, frequently progresses to type 2 diabetes. Loss of β-cell function and impaired insulin sensitivity both contribute to the development of diabetes (</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="12420" xml_f="12421" txt_i="7325" txt_f="7326">2</offsets></xref><offsets xml_i="12428" xml_f="12588" txt_i="7326" txt_f="7486">). β-Cell dysfunction may play a greater role than previously appreciated in that pancreatic β-cell apoptosis precedes overt diabetes in high-risk individuals (</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="12620" xml_f="12622" txt_i="7486" txt_f="7488">10</offsets></xref><offsets xml_i="12629" xml_f="12721" txt_i="7488" txt_f="7580">) and surgical reduction of pancreatic mass causes impaired glucose tolerance and diabetes (</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="12753" xml_f="12755" txt_i="7580" txt_f="7582">11</offsets></xref><offsets xml_i="12762" xml_f="12764" txt_i="7582" txt_f="7584">).</offsets></p><p><offsets xml_i="12771" xml_f="12952" txt_i="7585" txt_f="7766">To our knowledge, no prior human or animal studies have reported an effect of phosphodiesterase 5 inhibition on β-cell function. Pancreatic β-cells express endothelial NO synthase (</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="12984" xml_f="12986" txt_i="7766" txt_f="7768">12</offsets></xref><offsets xml_i="12993" xml_f="13154" txt_i="7768" txt_f="7929">). Previous studies provide conflicting data, however, regarding the effect of NO on β-cell function, with some suggesting that NO suppresses insulin secretion (</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="13186" xml_f="13188" txt_i="7929" txt_f="7931">13</offsets></xref><offsets xml_i="13195" xml_f="13196" txt_i="7931" txt_f="7932">,</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="13228" xml_f="13230" txt_i="7932" txt_f="7934">14</offsets></xref><offsets xml_i="13237" xml_f="13297" txt_i="7934" txt_f="7994">) and others indicating that NO enhances insulin secretion (</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="13329" xml_f="13331" txt_i="7994" txt_f="7996">12</offsets></xref><offsets xml_i="13338" xml_f="13339" txt_i="7996" txt_f="7997">,</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="13371" xml_f="13373" txt_i="7997" txt_f="7999">15</offsets></xref><offsets xml_i="13380" xml_f="13382" txt_i="7999" txt_f="8001">).</offsets></p><p><offsets xml_i="13389" xml_f="13786" txt_i="8002" txt_f="8399">Tadalafil improved islet cell function in women studied but not in men. A higher frequency of fasting hyperglycemia among women with metabolic syndrome may have confounded this sex difference. Alternatively, women may be more sensitive than men to decreased cGMP degradation. In support of this possibility, three of six women studied, but no men, reported muscle aches during tadalafil treatment.</offsets></p><p><offsets xml_i="13793" xml_f="13878" txt_i="8400" txt_f="8485">ACEIs improve glucose homeostasis or decrease diabetes incidence in clinical trials (</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="13909" xml_f="13910" txt_i="8485" txt_f="8486">4</offsets></xref><offsets xml_i="13917" xml_f="14101" txt_i="8486" txt_f="8670">). Although ACEIs and ARBs improve glucose uptake and/or insulin secretion in vitro and in rodents, studies in humans provide mixed data regarding their effects on insulin resistance (</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="14132" xml_f="14133" txt_i="8670" txt_f="8671">4</offsets></xref><offsets xml_i="14140" xml_f="14390" txt_i="8671" txt_f="8921">). We did not detect an effect of ramipril on insulin sensitivity or β-cell function but did detect an effect of ramipril on disposition index in women. Tadalafil enhanced this effect, again suggesting cGMP-dependent improvement in insulin secretion.</offsets></p><p><offsets xml_i="14397" xml_f="14762" txt_i="8922" txt_f="9287">Tadalafil improves β-cell function in metabolic syndrome. Studies are needed to determine whether the effect of tadalafil is limited to women or related to the magnitude of hyperglycemia. Given the increasing role attributed to β-cell dysfunction in the pathogenesis of type 2 diabetes, these data suggest a novel therapeutic intervention in a high-risk population.</offsets></p></sec><offsets xml_i="14772" xml_f="14773" txt_i="9289" txt_f="9290">
</offsets><sec sec-type="supplementary-material"><offsets xml_i="14812" xml_f="14813" txt_i="9290" txt_f="9291">
</offsets><title><offsets xml_i="14820" xml_f="14842" txt_i="9291" txt_f="9313">Supplementary Material</offsets></title><offsets xml_i="14850" xml_f="14851" txt_i="9314" txt_f="9315">
</offsets><supplementary-material id="PMC_1" content-type="local-data"><offsets xml_i="14912" xml_f="14913" txt_i="9315" txt_f="9316">
</offsets><caption><offsets xml_i="14922" xml_f="14923" txt_i="9316" txt_f="9317">
</offsets><title><offsets xml_i="14930" xml_f="14950" txt_i="9317" txt_f="9337">Online-Only Appendix</offsets></title><offsets xml_i="14958" xml_f="14959" txt_i="9338" txt_f="9339">
</offsets></caption><offsets xml_i="14969" xml_f="14970" txt_i="9339" txt_f="9340">
</offsets><media mimetype="text" mime-subtype="html" xlink:href="dc08-1862_index.html"></media><offsets xml_i="15055" xml_f="15056" txt_i="9340" txt_f="9341">
</offsets><media xlink:role="associated-file" mimetype="application" mime-subtype="msword" xlink:href="dc08-1862_dc08-1862_Online_appendix.doc"></media><offsets xml_i="15198" xml_f="15199" txt_i="9341" txt_f="9342">
</offsets></supplementary-material><offsets xml_i="15224" xml_f="15225" txt_i="9342" txt_f="9343">
</offsets></sec><offsets xml_i="15231" xml_f="15232" txt_i="9344" txt_f="9345">
</offsets></body><back><fn-group><fn fn-type="financial-disclosure"><p>The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.</p></fn><fn fn-type="other"><p>Clinical trial reg. no. NCT00750308, clinicaltrials.gov.</p></fn></fn-group><ack><title>Acknowledgments</title><p>No potential conflicts of interest relevant to this article were reported.</p><p>Parts of this study were presented in poster form at the 110th annual meeting of the American Society for Clinical Pharmacology and Therapeutics, Washington, D.C., 18–21 March 2009.</p><p>We acknowledge the contributions of Loretta Byrne, RN, for her excellent nursing support and David Wasserman, PhD, for his input regarding the manuscript.</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>ES</given-names></name><name><surname>Giles</surname><given-names>WH</given-names></name><name><surname>Dietz</surname><given-names>WH</given-names></name></person-group>:
<article-title>Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey</article-title>.
<source>JAMA</source><year>2002</year>;
<volume>287</volume>:
<fpage>356</fpage>–
<lpage>359</lpage><pub-id pub-id-type="pmid">11790215</pub-id></citation></ref><ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kahn</surname><given-names>SE</given-names></name></person-group>:
<article-title>The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes</article-title>.
<source>Diabetologia</source><year>2003</year>;
<volume>46</volume>:
<fpage>3</fpage>–
<lpage>19</lpage><pub-id pub-id-type="pmid">12637977</pub-id></citation></ref><ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meier</surname><given-names>JJ</given-names></name></person-group>:
<article-title>Beta cell mass in diabetes: a realistic therapeutic target?</article-title><source>Diabetologia</source><year>2008</year>;
<volume>51</volume>:
<fpage>703</fpage>–
<lpage>713</lpage><pub-id pub-id-type="pmid">18317728</pub-id></citation></ref><ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scheen</surname><given-names>AJ</given-names></name></person-group>:
<article-title>Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system</article-title>.
<source>Drugs</source><year>2004</year>;
<volume>64</volume>:
<fpage>2537</fpage>–
<lpage>2565</lpage><pub-id pub-id-type="pmid">15516153</pub-id></citation></ref><ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Velloso</surname><given-names>LA</given-names></name><name><surname>Folli</surname><given-names>F</given-names></name><name><surname>Sun</surname><given-names>XJ</given-names></name><name><surname>White</surname><given-names>MF</given-names></name><name><surname>Saad</surname><given-names>MJ</given-names></name><name><surname>Kahn</surname><given-names>CR</given-names></name></person-group>:
<article-title>Cross-talk between the insulin and angiotensin signaling systems</article-title>.
<source>Proc Natl Acad Sci U S A</source><year>1996</year>;
<volume>93</volume>:
<fpage>12490</fpage>–
<lpage>12495</lpage><pub-id pub-id-type="pmid">8901609</pub-id></citation></ref><ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>T</given-names></name><name><surname>Carlsson</surname><given-names>PO</given-names></name><name><surname>Leung</surname><given-names>PS</given-names></name></person-group>:
<article-title>Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets</article-title>.
<source>Diabetologia</source><year>2004</year>;
<volume>47</volume>:
<fpage>240</fpage>–
<lpage>248</lpage><pub-id pub-id-type="pmid">14722647</pub-id></citation></ref><ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shiuchi</surname><given-names>T</given-names></name><name><surname>Cui</surname><given-names>TX</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Nakagami</surname><given-names>H</given-names></name><name><surname>Takeda-Matsubara</surname><given-names>Y</given-names></name><name><surname>Iwai</surname><given-names>M</given-names></name><name><surname>Horiuchi</surname><given-names>M</given-names></name></person-group>:
<article-title>ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and, NO</article-title>.
<source>Hypertension</source><year>2002</year>;
<volume>40</volume>:
<fpage>329</fpage>–
<lpage>334</lpage><pub-id pub-id-type="pmid">12215475</pub-id></citation></ref><ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ayala</surname><given-names>JE</given-names></name><name><surname>Bracy</surname><given-names>DP</given-names></name><name><surname>Julien</surname><given-names>BM</given-names></name><name><surname>Rottman</surname><given-names>JN</given-names></name><name><surname>Fueger</surname><given-names>PT</given-names></name><name><surname>Wasserman</surname><given-names>DH</given-names></name></person-group>:
<article-title>Chronic treatment with sildenafil improves energy balance and insulin action in high fat–fed conscious mice</article-title>.
<source>Diabetes</source><year>2007</year>;
<volume>56</volume>:
<fpage>1025</fpage>–
<lpage>1033</lpage><pub-id pub-id-type="pmid">17229936</pub-id></citation></ref><ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ishikawa</surname><given-names>T</given-names></name><name><surname>Kaneko</surname><given-names>Y</given-names></name><name><surname>Sugino</surname><given-names>F</given-names></name><name><surname>Nakayama</surname><given-names>K</given-names></name></person-group>:
<article-title>Two distinct effects of cGMP on cytosolic Ca2+ concentration of rat pancreatic beta-cells</article-title>.
<source>J Pharmacol Sci</source><year>2003</year>;
<volume>91</volume>:
<fpage>41</fpage>–
<lpage>46</lpage><pub-id pub-id-type="pmid">12686729</pub-id></citation></ref><ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smukler</surname><given-names>SR</given-names></name><name><surname>Tang</surname><given-names>L</given-names></name><name><surname>Wheeler</surname><given-names>MB</given-names></name><name><surname>Salapatek</surname><given-names>AM</given-names></name></person-group>:
<article-title>Exogenous nitric oxide and endogenous glucose-stimulated β-cell nitric oxide augment insulin release</article-title>.
<source>Diabetes</source><year>2002</year>;
<volume>51</volume>:
<fpage>3450</fpage>–
<lpage>3460</lpage><pub-id pub-id-type="pmid">12453899</pub-id></citation></ref><ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kendall</surname><given-names>DM</given-names></name><name><surname>Sutherland</surname><given-names>DE</given-names></name><name><surname>Najarian</surname><given-names>JS</given-names></name><name><surname>Goetz</surname><given-names>FC</given-names></name><name><surname>Robertson</surname><given-names>RP</given-names></name></person-group>:
<article-title>Effects of hemipancreatectomy on insulin secretion and glucose tolerance in healthy humans</article-title>.
<source>N Engl J Med</source><year>1990</year>;
<volume>322</volume>:
<fpage>898</fpage>–
<lpage>903</lpage><pub-id pub-id-type="pmid">2179721</pub-id></citation></ref><ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>HH</given-names></name><name><surname>Warner</surname><given-names>TD</given-names></name><name><surname>Ishii</surname><given-names>K</given-names></name><name><surname>Sheng</surname><given-names>H</given-names></name><name><surname>Murad</surname><given-names>F</given-names></name></person-group>:
<article-title>Insulin secretion from pancreatic B cells caused by L-arginine-derived nitrogen oxides</article-title>.
<source>Science</source><year>1992</year>;
<volume>255</volume>:
<fpage>721</fpage>–
<lpage>723</lpage><pub-id pub-id-type="pmid">1371193</pub-id></citation></ref><ref id="B13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cunningham</surname><given-names>JM</given-names></name><name><surname>Mabley</surname><given-names>JG</given-names></name><name><surname>Delaney</surname><given-names>CA</given-names></name><name><surname>Green</surname><given-names>IC</given-names></name></person-group>:
<article-title>The effect of nitric oxide donors on insulin secretion, cyclic GMP and cyclic AMP in rat islets of Langerhans and the insulin-secreting cell lines HIT-T15 and RINm5F</article-title>.
<source>Mol Cell Endocrinol</source><year>1994</year>;
<volume>102</volume>:
<fpage>23</fpage>–
<lpage>29</lpage><pub-id pub-id-type="pmid">7926270</pub-id></citation></ref><ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Panagiotidis</surname><given-names>G</given-names></name><name><surname>Akesson</surname><given-names>B</given-names></name><name><surname>Rydell</surname><given-names>EL</given-names></name><name><surname>Lundquist</surname><given-names>I</given-names></name></person-group>:
<article-title>Influence of nitric oxide synthase inhibition, nitric oxide and hydroperoxide on insulin release induced by various secretagogues</article-title>.
<source>Br J Pharmacol</source><year>1995</year>;
<volume>114</volume>:
<fpage>289</fpage>–
<lpage>296</lpage><pub-id pub-id-type="pmid">7533613</pub-id></citation></ref><ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>Y</given-names></name><name><surname>Rana</surname><given-names>RS</given-names></name></person-group>:
<article-title>Nitric oxide does not initiate but potentiates glucose-induced insulin secretion in pancreatic beta-cells</article-title>.
<source>Biochem Biophys Res Commun</source><year>1998</year>;
<volume>251</volume>:
<fpage>699</fpage>–
<lpage>703</lpage><pub-id pub-id-type="pmid">9790972</pub-id></citation></ref></ref-list></back></article>